New Psoriasis Data and Treatment Advancements from AAD Annual Meeting
- The American Academy of Dermatology Annual Meeting featured a wide array of new data concerning the treatment of psoriasis, highlighting several emerging therapies and new clinical findings.
- Among the notable updates was the presentation of new data regarding icotrokinra, marketed as Icotyde and developed by Johnson & Johnson, which is a recently FDA-approved treatment.
- The meeting also showcased developments in next-generation tyrosine kinase inhibitors.
The American Academy of Dermatology Annual Meeting featured a wide array of new data concerning the treatment of psoriasis, highlighting several emerging therapies and new clinical findings. Joseph F. Merola, MD, MMSc, FAAD, noted that the volume of data presented provided significant opportunities for analysis and optimism within the field of psoriasis care.
Among the notable updates was the presentation of new data regarding icotrokinra, marketed as Icotyde and developed by Johnson & Johnson, which is a recently FDA-approved treatment.
The meeting also showcased developments in next-generation tyrosine kinase inhibitors. Specifically, data was presented on izasocitinib, developed by Takeda, and envudeucitinib, developed by Alumis Inc.
Research into combination therapies was another key focus of the proceedings. Data was shared on the combined use of ixekizumab, known as Taltz, and tirzepatide, known as Zepbound; both medications are developed by Eli Lilly.
the meeting included the presentation of results from the TOGETHER-PsO study, contributing to the broader understanding of current psoriasis treatment strategies.